piromelatine (Neu P11) / Neurim 
Welcome,         Profile    Billing    Logout  
 14 Diseases   1 Trial   1 Trial   38 News 
  • ||||||||||  piromelatine (Neu P11) / Neurim
    Preclinical, Journal:  Sex-Dependent Effect of Chronic Piromelatine Treatment on Prenatal Stress-Induced Memory Deficits in Rats. (Pubmed Central) -  Jan 22, 2023   
    While the ratio of phosphorylated and nonphosphorylated adenosine monophosphate response element binding protein (pCREB/CREB) was reduced in the two sexes with PNS and treated with a vehicle, the melatonin analogue elevated the ratio of these signaling molecules in the hippocampus of the male rats only. Our results suggest that Piromelatine exerts a beneficial effect on PNS-induced spatial memory impairment in a sex-dependent manner that might be mediated via the pCREB/CREB pathway.
  • ||||||||||  piromelatine (Neu P11) / Neurim
    Preclinical, Journal:  Sex-Dependent Effects of Piromelatine Treatment on Sleep-Wake Cycle and Sleep Structure of Prenatally Stressed Rats. (Pubmed Central) -  Oct 1, 2022   
    In addition, Pir increased the BDNF expression in the hippocampus in male and female offspring with PNS. Our findings suggest that the beneficial effect of Pir on PNS-induced impairment of sleep/wake cycle circadian rhythm and sleep structure is exerted via activation of MT receptors and enhanced BDNF expression in the hippocampus in male and female offspring.
  • ||||||||||  piromelatine (Neu P11) / Neurim
    Preclinical, Journal:  Neu-P11, a novel melatonin receptor agonist, could improve the features of type-2 diabetes mellitus in rats. (Pubmed Central) -  Mar 29, 2022   
    These findings warrant further investigation in a larger, prospective early-stage AD clinical trial for patients who are non-carriers of the 2q12 polymorphism cluster. Melatonin and its receptor Neu-P11 can reduce the blood glucose level, enhance humoral and cellular immunity, inhibit microglia activation and inflammation, and repair isletβ cell function, and this improve the characterization of T2DM-related diseases.
  • ||||||||||  Hetlioz (tasimelteon) / Vanda, piromelatine (Neu P11) / Neurim
    Review, Journal:  Antidepressant actions of melatonin and melatonin receptor agonist: Focus on pathophysiology and treatment. (Pubmed Central) -  Mar 11, 2022   
    The present review summarizes the mechanisms underlying the antidepressant effects of melatonin, which is related to its functions in the regulation of the hypothalamic-pituitary-adrenal axis, inhibition of neuroinflammation, inhibition of oxidative stress, alleviation of autophagy, and upregulation of neurotrophic, promotion of neuroplasticity and upregulation of the levels of neurotransmitters, etc. Also, melatonin receptor agonists, such as agomelatine, ramelteon, piromelatine, tasimelteon, and GW117, have received considerable critical attention and are highly implicated in treating depression and comorbid disorders. This review focuses on melatonin and various melatonin receptor agonists in the pathophysiology and treatment of depression, aiming to provide further insight into the pathogenesis of depression and explore potential targets for novel agent development.
  • ||||||||||  Journal:  The role of melatonin and its analogues in epilepsy. (Pubmed Central) -  Sep 21, 2020   
    Our review is suggestive of antiseizure effects of both melatonin and its analogues; however, extensive research work is still required to study their implications in the treatment of persons with epilepsy. Further evaluation of melatonergic signaling pathways and mechanisms may prove to be helpful in the near future and might prove to be a significant advance in the field of epileptology.
  • ||||||||||  piromelatine (Neu P11) / Neurim
    Trial completion, Trial primary completion date:  Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION) (clinicaltrials.gov) -  Feb 26, 2020   
    P2,  N=500, Completed, 
    Conclusion This study suggests that the novel melatoninergic drug Pir is able to alleviate anxiety and depressive responses via restoration of the impaired HPA axis feedback mechanism in PNS female offspring. Active, not recruiting --> Completed | Trial primary completion date: Nov 2019 --> Jun 2019
  • ||||||||||  piromelatine (Neu P11) / Neurim
    Trial completion date, Trial primary completion date:  Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION) (clinicaltrials.gov) -  Aug 21, 2019   
    P2,  N=500, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Nov 2019 --> Jun 2019 Trial completion date: Apr 2019 --> Nov 2019 | Trial primary completion date: Apr 2019 --> Nov 2019
  • ||||||||||  piromelatine (Neu P11) / Neurim
    Trial completion date, Trial primary completion date:  Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION) (clinicaltrials.gov) -  Apr 11, 2018   
    P2,  N=500, Recruiting, 
    Trial completion date: Apr 2019 --> Nov 2019 | Trial primary completion date: Apr 2019 --> Nov 2019 Trial completion date: Mar 2018 --> Apr 2019 | Trial primary completion date: Mar 2018 --> Apr 2019
  • ||||||||||  piromelatine (Neu P11) / Neurim
    Enrollment open, Trial primary completion date:  Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION) (clinicaltrials.gov) -  Jun 29, 2016   
    P2,  N=500, Recruiting, 
    Trial completion date: Mar 2018 --> Apr 2019 | Trial primary completion date: Mar 2018 --> Apr 2019 Suspended --> Recruiting | Trial primary completion date: Dec 2017 --> Mar 2018
  • ||||||||||  piromelatine (Neu P11) / Neurim
    Trial completion:  The Effect of Neu-P11 on Symptoms in Patients With D-IBS (clinicaltrials.gov) -  Feb 3, 2014   
    P=N/A,  N=40, Completed, 
    Not yet recruiting --> Recruiting Enrolling by invitation --> Completed